Alliance Pharma plc (APH.L) Update Acquisition – an eye to future growth
With the trading statement suggesting underlying performance in line withexpectations, the acquisition of MacuVision is immediately earnings and ROIC
enhancing. Coupled with the prospect of re-supplying ImmuCyst in 2015, at a time when
the incumbent is facing supply constraints, Alliance is expected to return to solid and
sustainable earnings growth with improving financial metrics.
Alliance Pharma is a holding company. Co. is engaged in the acquisition, marketing and distribution of pharmaceutical and other medical products.
We are a rapidly growing, innovative corporate research & consultancy business, based in London, serving the needs of both public and private companies.
Our expert team of sector analysts and market professionals collectively have over 400 years of experience. This depth of knowledge and a reputation for integrity have built trust with investors. With effective communication and precision distribution, we help companies disseminate their investment message to interested investors, as well as advise them on strategy.
Our smaller, boutique structure allows us to provide first-class customer service and to deliver a wide range of ad-hoc services for multiple clients with different needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.